Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.55 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 6/20 | 0.45 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21526292 | 1.00 | ELANE (0.55) | ELANEXIAPMLXCMA1CTSG | |
| SCHEMBL18100584 | 0.90 | ELANE (0.49) | ELANEXIAPMLXCMA1CTSG | |
| SCHEMBL20747589 | 0.90 | ELANE (0.49) | ELANEXIAPMLXCMA1CTSG | |
| SCHEMBL20747625 | 0.90 | ELANE (0.49) | ELANEXIAPMLXCMA1CTSG | |
| SCHEMBL20859022 | 0.89 | CMA1 (0.58) | ELANECMA1 | |
| SCHEMBL18103339 | 0.89 | CMA1 (0.58) | ELANECMA1 | |
| SCHEMBL28390853 | 0.89 | CMA1 (0.58) | ELANECMA1 | |
| SCHEMBL16703830 | 0.88 | ELANE (0.48) | ELANEXIAPMLX | |
| SCHEMBL16703831 | 0.88 | ELANE (0.48) | ELANEXIAPMLX | |
| SCHEMBL20859027 | 0.88 | ELANE (0.48) | ELANEXIAPMLX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10207994-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2019-02-19 | — | — | US | claimed |
| EP-4001272-A1 | NMDA ANTAGONIST PRODRUGS | Astrazeneca AB (SE) | 2022-05-25 | — | — | EP | disclosed |
| EP-3564234-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2021-09-29 | — | — | EP | disclosed |
| US-20210040039-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2021-02-11 | — | — | US | disclosed |
| US-10815199-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2020-10-27 | — | — | US | disclosed |
| EP-3564234-A1 | NMDA ANTAGONIST PRODRUGS | AstraZeneca AB (SE) | 2019-11-06 | — | — | EP | disclosed |
| US-20190152914-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2019-05-23 | — | — | US | disclosed |
| EP-3066091-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2019-04-03 | — | — | EP | disclosed |
| US-10207994-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2019-02-19 | — | — | US | disclosed |
| US-20180037550-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2018-02-08 | — | — | US | disclosed |
| US-9822075-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2017-11-21 | — | — | US | disclosed |
| US-20160280647-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2016-09-29 | — | — | US | disclosed |
| EP-3066091-A1 | NMDA ANTAGONIST PRODRUGS | Astrazeneca AB (SE) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015067923-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040039-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885XIAP 3854/4885MLX 3720/4885 |
| US-10815199-B2 | NMDA antagonist prodrugs | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885XIAP 3854/4885MLX 3720/4885 |
| US-10207994-B2 | NMDA antagonist prodrugs | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885XIAP 3854/4885MLX 3720/4885 |
| US-20190152914-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885XIAP 3854/4885MLX 3720/4885 |
| US-20160280647-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885XIAP 3854/4885MLX 3720/4885 |
| US-20180037550-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885XIAP 3854/4885MLX 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.